2012 marks the 30th anniversary of Immucor's founding in 1982. We appreciate the many customers we have had the privilege of serving over this time. We would like to take this opportunity to thank everyone for their interest and their business throughout the years.
We are solely dedicated to transfusion medicine and have been since our inception. Every one of our 900 employees works to improve lives and help our customers ensure a safe blood supply, which is our passion and our focus. Our track record and strength come from our passion for the patient and individuals in the laboratory who work so diligently to serve the patient.
For nearly two decades, we built our business by making great products for the traditional immunohematology laboratories. In the last decade, we have launched four generations of fully automated instrumentation to improve productivity and standardization in immunohematology labs worldwide. From the ABS2000® through to Galileo®, Echo® and NEO®, we have innovated and adapted our Capture® solid phase technology and hemagglutination methods for multiple segments of the market from the largest Donor Center, the Immunohematology Reference Laboratory and a small Transfusion Service. In the North American market, we have the broadest line of reagents and configuration of products to satisfy the needs of any customer.
Our solutions enhance transfusion practice now and in the future because there have been significant investments to building our product line. In 1999, we added Gamma Biologicals to our portfolio to create greater benefits for our customers. Recently, we have added BioArray Solutions to expand into the next frontier of transfusion medicine. Our investments continue, as we have doubled our size in the last six years. Our growth continues as we hire across every department and prepare to provide solutions that fit unique needs of different size labs.
Shortly, we will release a treponemal test for syphilis on our Galileo® and NEO® instruments followed by a new FMH RapidScreen fetal maternal hemorrhage screening test that has a five-minute room temperature incubation, which is ideal for laboratories looking to quickly screen risk in D-negative mothers with D-positive babies.
We are also proud to launch ImmuLINK™, our cutting-edge data management solution. The recently acquired FDA clearance on ImmuLINK| manage will enable us to complement our automated scalable solutions with an innovative software suite designed specifically for Transfusion Medicine.
With additional funding from our new owners, TPG Capital, we are thrilled to accelerate our investments for laboratories like yours around the world to improve patient safety.